| Self-reactive IgE exacerbates interferon responses associated with autoimmunity J Henault, JM Riggs, JL Karnell, VM Liarski, J Li, L Shirinian, L Xu, ... Nature immunology 17 (2), 196-203, 2016 | 146 | 2016 |
| Serum glial fibrillary acidic protein: a neuromyelitis optica spectrum disorder biomarker O Aktas, MA Smith, WA Rees, JL Bennett, D She, E Katz, BAC Cree, ... Annals of neurology 89 (5), 895-910, 2021 | 92 | 2021 |
| Hepatitis delta virus detected in salivary glands of Sjögren's syndrome patients and recapitulates a Sjögren's syndrome-like phenotype in vivo ML Weller, MR Gardener, ZC Bogus, MA Smith, E Astorri, DG Michael, ... Pathogens & immunity 1 (1), 12, 2016 | 65 | 2016 |
| Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE KA Casey, X Guo, MA Smith, S Wang, D Sinibaldi, MA Sanjuan, L Wang, ... Lupus Science & Medicine 5 (1), e000286, 2018 | 64 | 2018 |
| Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus JL Karnell, Y Wu, N Mittereder, MA Smith, M Gunsior, L Yan, KA Casey, ... Science translational medicine 13 (595), eabf8442, 2021 | 60 | 2021 |
| Modulation of cardiometabolic disease markers by type I interferon inhibition in systemic lupus erythematosus KA Casey, MA Smith, D Sinibaldi, NL Seto, MP Playford, X Wang, ... Arthritis & Rheumatology 73 (3), 459-471, 2021 | 45 | 2021 |
| Natural killer cell expression of Ki67 is associated with elevated serum IL-15, disease activity and nephritis in systemic lupus erythematosus K Hudspeth, S Wang, J Wang, S Rahman, MA Smith, KA Casey, ... Clinical & Experimental Immunology 196 (2), 226-236, 2019 | 31 | 2019 |
| Disability outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder R Marignier, JL Bennett, HJ Kim, BG Weinshenker, SJ Pittock, ... Neurology: Neuroimmunology & Neuroinflammation 8 (3), e978, 2021 | 28 | 2021 |
| SLE plasma profiling identifies unique signatures of lupus nephritis and discoid lupus MA Smith, J Henault, JL Karnell, ML Parker, JM Riggs, D Sinibaldi, ... Scientific reports 9 (1), 14433, 2019 | 22 | 2019 |
| AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder R Marignier, SJ Pittock, F Paul, HJ Kim, JL Bennett, BG Weinshenker, ... Multiple Sclerosis and Related Disorders 57, 103356, 2022 | 20 | 2022 |
| Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus MA Smith, CC Chiang, K Zerrouki, S Rahman, WI White, K Streicher, ... Scientific Reports 10 (1), 4462, 2020 | 19 | 2020 |
| Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo … JL Bennett, O Aktas, WA Rees, MA Smith, M Gunsior, L Yan, D She, ... EBioMedicine 86, 2022 | 12 | 2022 |
| Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in … O Aktas, HP Hartung, MA Smith, WA Rees, K Fujihara, F Paul, R Marignier, ... Journal of Neurology, Neurosurgery & Psychiatry 94 (9), 757-768, 2023 | 8 | 2023 |
| OP0174 Alteration of mediators of vascular inflammation by anifrolumab in the phase iib muse study in sle WI White, NL Seto, MP Playford, KA Casey, MA Smith, P Carlucci, B Yu, ... Annals of the Rheumatic Diseases 77 (Suppl 2), 136-137, 2018 | 5 | 2018 |
| Shared and distinctive transcriptomic and proteomic pathways in adult and juvenile dermatomyositis JM Ward, M Ambatipudi, TP O'Hanlon, MA Smith, M de Los Reyes, ... Arthritis & Rheumatology 75 (11), 2014-2026, 2023 | 3 | 2023 |
| Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum BG Weinshenker, DM Wingerchuk, AJ Green, JL Bennett, HJ Kim, ... Multiple Sclerosis Journal 29 (8), 945-955, 2023 | 3 | 2023 |
| Extent of B-cell depletion is associated with disease activity reduction in neuromyelitis optica spectrum disorder: results from the N-MOmentum study JL Bennett, O Aktas, M Smith, WA Rees, E Katz, BAC Cree MULTIPLE SCLEROSIS JOURNAL 27 (2_ SUPPL), 151-152, 2021 | 2 | 2021 |
| (DAM04) Serum Glial Fibrillary Acidic Protein Is Elevated in a Subset of Neuromyelitis Optica Patients and Associated with Increased Risk of Attacks. HP Hartung, O Aktas, MA Smith, W Rees, K Fujihara, F Paul, R Marignier, ... International Journal of MS Care 22, 2020 | 2 | 2020 |
| Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism HJ Kim, O Aktas, KR Patterson, S Korff, A Kunchok, JL Bennett, ... Annals of Clinical and Translational Neurology 10 (12), 2413-2420, 2023 | 1 | 2023 |
| Inebilizumab Reduces Attack Risk Independent of Low Affinity IgG Fc Region Receptor III-A Gene Polymorphisms in Neuromyelitis Optica Spectrum Disorder (P13-5.015) B Weinshenker, J Bennett, B Cree, F Paul, HJ Kim, HP Hartung, ... Neurology 100 (17 Supplement 2), 2023 | 1 | 2023 |
